Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 25;12(11):3662.
doi: 10.3390/jcm12113662.

Drug Coated Balloon in the Treatment of De Novo Coronary Artery Disease: A Narrative Review

Filippo Zilio  1 , Monica Verdoia  2 , Maria Carmen De Angelis  3 , Federico Zucchelli  1 , Marco Borghesi  1 , Andrea Rognoni  2 , Roberto Bonmassari  1
Affiliations
Review

Drug Coated Balloon in the Treatment of De Novo Coronary Artery Disease: A Narrative Review

Filippo Zilio et al. J Clin Med. .

Abstract

Drug coated balloons (DCBs) are currently indicated in guidelines as a first choice option in the management of instant restenosis, whereas their use in de novo lesions is still debated. The concerns raised after the contrasting results of the initial trials with DCBs in de novo lesions have been more recently overcome by a larger amount of data confirming their safety and effectiveness as compared to drug-eluting stents (DES), with potentially greater benefits being achieved, especially in particular anatomical settings, as in very small or large vessels and bifurcations, but also in selected subsets of higher-risk patients, where a 'leave nothing behind' strategy could offer a reduction of the inflammatory stimulus and thrombotic risk. The present review aims at providing an overview of current available DCB devices and their indications of use based on the results of data achieved so far.

Keywords: drug coated balloon; paclitaxel; percutaneous coronary artery intervention; sirolimus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Central figure.
See this image and copyright information in PMC

References

    1. Alfonso F., Scheller B. State of the art: Balloon catheter technologies—Drug-coated balloon. Eurointervention. 2017;13:680–695. doi: 10.4244/EIJ-D-17-00494. - DOI - PubMed
    1. Byrne R., Joner M., Alfonso F., Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat. Rev. Cardiol. 2014;11:13–23. doi: 10.1038/nrcardio.2013.165. - DOI - PubMed
    1. Cheng Y., Leon M.B., Granada J.F. An update on the clinical use of drug-coated balloons in percutaneous coronary interventions. Expert Opin. Drug Deliv. 2016;13:859–872. doi: 10.1517/17425247.2016.1154530. - DOI - PubMed
    1. Elgendy I.Y., Gad M.M., Elgendy A.Y., Mahmoud A., Mahmoud A.N., Cuesta J., Rivero F., Alfonso F. Clinical and Angiographic Outcomes with Drug-Coated Balloons for De Novo Coronary Lesions: A Meta-Analysis of Randomized Clinical Trials. J. Am. Heart Assoc. 2020;18:e016224. doi: 10.1161/JAHA.120.016224. - DOI - PMC - PubMed
    1. Verdoia M., Negro F., Kedhi E., Suryapranata H., Marcolongo M., De Luca G. Benefits with drug-coated balloon as com-pared to a conventional revascularization strategy for the treatment of coronary and non-coronary arterial disease: A comprehensive meta-analysis of 45 randomized trials. Vascul. Pharmacol. 2021;138:106859. doi: 10.1016/j.vph.2021.106859. - DOI - PubMed

LinkOut - more resources